TY - JOUR
T1 - Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
AU - Smid, Marcel
AU - Rodríguez-González, F. Germán
AU - Sieuwerts, Anieta M.
AU - Salgado, Roberto
AU - Prager-Van der Smissen, Wendy J. C.
AU - Vlugt-Daane, Michelle van der
AU - van Galen, Anne
AU - Nik-Zainal, Serena
AU - Staaf, Johan
AU - Brinkman, Arie B.
AU - van de Vijver, Marc J.
AU - Richardson, Andrea L.
AU - Fatima, Aquila
AU - Berentsen, Kim
AU - Butler, Adam
AU - Martin, Sancha
AU - Davies, Helen R.
AU - Debets, Reno
AU - Gelder, Marion E. Meijer-Van
AU - van Deurzen, Carolien H. M.
AU - MacGrogan, Gaëtan
AU - Van den Eynden, Gert G. G. M.
AU - Purdie, Colin
AU - Thompson, Alastair M.
AU - Caldas, Carlos
AU - Span, Paul N.
AU - Simpson, Peter T.
AU - Lakhani, Sunil R.
AU - Van Laere, Steven
AU - Desmedt, Christine
AU - Ringnér, Markus
AU - Tommasi, Stefania
AU - Eyford, Jorunn
AU - Broeks, Annegien
AU - Vincent-Salomon, Anne
AU - Futreal, P. Andrew
AU - Knappskog, Stian
AU - King, Tari
AU - Thomas, Gilles
AU - Viari, Alain
AU - Langerød, Anita
AU - Børresen-Dale, Anne-Lise
AU - Birney, Ewan
AU - Stunnenberg, Hendrik G.
AU - Stratton, Mike
AU - Foekens, John A.
AU - Martens, John W. M.
N1 - This work has been funded through the ICGC Breast Cancer Working group by the Breast Cancer Somatic Genetics Study (a European research project funded by the European Community’s Seventh Framework Programme (FP7/2010-2014) under the grant agreement number 242006); the Triple Negative project funded by the Wellcome Trust (grant reference 077012/Z/05/Z).
PY - 2016/9/26
Y1 - 2016/9/26
N2 - A recent comprehensive whole genome analysis of a large breast cancer cohort was used to link known and novel drivers and substitution signatures to the transcriptome of 266 cases. Here, we validate that subtype-specific aberrations show concordant expression changes for, for example, TP53, PIK3CA, PTEN, CCND1 and CDH1. We find that CCND3 expression levels do not correlate with amplification, while increased GATA3 expression in mutant GATA3 cancers suggests GATA3 is an oncogene. In luminal cases the total number of substitutions, irrespective of type, associates with cell cycle gene expression and adverse outcome, whereas the number of mutations of signatures 3 and 13 associates with immune-response specific gene expression, increased numbers of tumour-infiltrating lymphocytes and better outcome. Thus, while earlier reports imply that the sheer number of somatic aberrations could trigger an immune-response, our data suggests that substitutions of a particular type are more effective in doing so than others.
AB - A recent comprehensive whole genome analysis of a large breast cancer cohort was used to link known and novel drivers and substitution signatures to the transcriptome of 266 cases. Here, we validate that subtype-specific aberrations show concordant expression changes for, for example, TP53, PIK3CA, PTEN, CCND1 and CDH1. We find that CCND3 expression levels do not correlate with amplification, while increased GATA3 expression in mutant GATA3 cancers suggests GATA3 is an oncogene. In luminal cases the total number of substitutions, irrespective of type, associates with cell cycle gene expression and adverse outcome, whereas the number of mutations of signatures 3 and 13 associates with immune-response specific gene expression, increased numbers of tumour-infiltrating lymphocytes and better outcome. Thus, while earlier reports imply that the sheer number of somatic aberrations could trigger an immune-response, our data suggests that substitutions of a particular type are more effective in doing so than others.
U2 - 10.1038/ncomms12910
DO - 10.1038/ncomms12910
M3 - Article
C2 - 27666519
SN - 2041-1723
VL - 7
SP - 1
EP - 9
JO - Nature Communications
JF - Nature Communications
M1 - 12910
ER -